CA2602681C - Detecting and predicting pre-eclampsia - Google Patents
Detecting and predicting pre-eclampsia Download PDFInfo
- Publication number
- CA2602681C CA2602681C CA2602681A CA2602681A CA2602681C CA 2602681 C CA2602681 C CA 2602681C CA 2602681 A CA2602681 A CA 2602681A CA 2602681 A CA2602681 A CA 2602681A CA 2602681 C CA2602681 C CA 2602681C
- Authority
- CA
- Canada
- Prior art keywords
- alpha
- mmp
- subject
- plgf
- stnf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 201000011461 pre-eclampsia Diseases 0.000 title claims abstract description 160
- 238000000034 method Methods 0.000 claims abstract description 79
- 238000009007 Diagnostic Kit Methods 0.000 claims abstract description 4
- 108010082093 Placenta Growth Factor Proteins 0.000 claims description 155
- 102000003666 Placenta Growth Factor Human genes 0.000 claims description 155
- 102000001776 Matrix metalloproteinase-9 Human genes 0.000 claims description 106
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 claims description 106
- 230000035935 pregnancy Effects 0.000 claims description 49
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims description 46
- 229940039781 leptin Drugs 0.000 claims description 46
- 230000035488 systolic blood pressure Effects 0.000 claims description 44
- 102000016267 Leptin Human genes 0.000 claims description 43
- 108010092277 Leptin Proteins 0.000 claims description 43
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 claims description 40
- 230000008774 maternal effect Effects 0.000 claims description 36
- 230000003205 diastolic effect Effects 0.000 claims description 29
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 claims description 23
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims description 23
- 210000000685 uterine artery Anatomy 0.000 claims description 22
- 230000017074 necrotic cell death Effects 0.000 claims description 21
- 230000036772 blood pressure Effects 0.000 claims description 16
- 102000004179 Plasminogen Activator Inhibitor 2 Human genes 0.000 claims description 9
- 108090000614 Plasminogen Activator Inhibitor 2 Proteins 0.000 claims description 9
- 230000004872 arterial blood pressure Effects 0.000 claims description 9
- 210000004369 blood Anatomy 0.000 claims description 9
- 239000008280 blood Substances 0.000 claims description 9
- 239000003153 chemical reaction reagent Substances 0.000 claims description 9
- 238000002604 ultrasonography Methods 0.000 claims description 9
- 230000001435 haemodynamic effect Effects 0.000 claims description 8
- 238000004422 calculation algorithm Methods 0.000 claims description 4
- 238000002965 ELISA Methods 0.000 claims description 3
- 230000033885 plasminogen activation Effects 0.000 claims description 3
- 238000010561 standard procedure Methods 0.000 claims description 2
- 238000001262 western blot Methods 0.000 claims description 2
- 239000000523 sample Substances 0.000 claims 23
- 102000012335 Plasminogen Activator Inhibitor 1 Human genes 0.000 claims 4
- 239000012472 biological sample Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000002797 plasminogen activator inhibitor Substances 0.000 claims 1
- 238000005516 engineering process Methods 0.000 abstract description 12
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 54
- 101000609261 Homo sapiens Plasminogen activator inhibitor 2 Proteins 0.000 description 38
- 102100039419 Plasminogen activator inhibitor 2 Human genes 0.000 description 38
- 238000012360 testing method Methods 0.000 description 28
- 230000035487 diastolic blood pressure Effects 0.000 description 23
- 101000609255 Homo sapiens Plasminogen activator inhibitor 1 Proteins 0.000 description 18
- 230000035945 sensitivity Effects 0.000 description 16
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 15
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 15
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 15
- 239000000893 inhibin Substances 0.000 description 15
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 15
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 13
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 13
- 102000002746 Inhibins Human genes 0.000 description 13
- 108010004250 Inhibins Proteins 0.000 description 13
- 239000003550 marker Substances 0.000 description 13
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 description 12
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 108010076365 Adiponectin Proteins 0.000 description 10
- 102000011690 Adiponectin Human genes 0.000 description 10
- 206010020772 Hypertension Diseases 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 101000610236 Nostoc sp. (strain PCC 7120 / SAG 25.82 / UTEX 2576) Protein PatA Proteins 0.000 description 7
- 102100037882 Perilipin-5 Human genes 0.000 description 7
- KRPUGSACBHJZSR-UHFFFAOYSA-N [3-oxo-2-phenyl-3-(pyridin-2-ylmethylamino)propyl] acetate Chemical compound C=1C=CC=CC=1C(COC(=O)C)C(=O)NCC1=CC=CC=N1 KRPUGSACBHJZSR-UHFFFAOYSA-N 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 101150101567 pat-2 gene Proteins 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 230000002159 abnormal effect Effects 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000012954 risk control Methods 0.000 description 6
- 238000001514 detection method Methods 0.000 description 5
- 238000007477 logistic regression Methods 0.000 description 5
- 201000001474 proteinuria Diseases 0.000 description 5
- 230000009466 transformation Effects 0.000 description 5
- 238000000844 transformation Methods 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 206010070538 Gestational hypertension Diseases 0.000 description 4
- 230000005856 abnormality Effects 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000003018 immunoassay Methods 0.000 description 4
- 238000012827 research and development Methods 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 description 3
- -1 Leptin Proteins 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- 239000000090 biomarker Substances 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 230000009469 supplementation Effects 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- 101100372758 Danio rerio vegfaa gene Proteins 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- 201000005624 HELLP Syndrome Diseases 0.000 description 2
- 101001094044 Mus musculus Solute carrier family 26 member 6 Proteins 0.000 description 2
- 206010036595 Premature delivery Diseases 0.000 description 2
- 101150030763 Vegfa gene Proteins 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 102000049113 human PGF Human genes 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 description 1
- 208000001362 Fetal Growth Retardation Diseases 0.000 description 1
- 206010070531 Foetal growth restriction Diseases 0.000 description 1
- 208000000091 Maternal Death Diseases 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 101150072055 PAL1 gene Proteins 0.000 description 1
- 102100035194 Placenta growth factor Human genes 0.000 description 1
- 208000005347 Pregnancy-Induced Hypertension Diseases 0.000 description 1
- 208000005107 Premature Birth Diseases 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000003150 biochemical marker Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 208000030941 fetal growth restriction Diseases 0.000 description 1
- 238000012886 linear function Methods 0.000 description 1
- 238000010234 longitudinal analysis Methods 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000010197 meta-analysis Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 238000012806 monitoring device Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 208000036335 preeclampsia/eclampsia 1 Diseases 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000009117 preventive therapy Methods 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 208000002254 stillbirth Diseases 0.000 description 1
- 231100000537 stillbirth Toxicity 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 210000002993 trophoblast Anatomy 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 235000019195 vitamin supplement Nutrition 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96486—Metalloendopeptidases (3.4.24)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
- G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
- Mold Materials And Core Materials (AREA)
- Optical Fibers, Optical Fiber Cores, And Optical Fiber Bundles (AREA)
- Adhesives Or Adhesive Processes (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Holo Graphy (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0600916.1A GB0600916D0 (en) | 2006-01-17 | 2006-01-17 | detecting and predicting pre-eclampsia |
| GB0600916.1 | 2006-01-17 | ||
| PCT/GB2007/000123 WO2007083099A1 (en) | 2006-01-17 | 2007-01-17 | Detecting and predicting pre-eclampsia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2602681A1 CA2602681A1 (en) | 2007-07-26 |
| CA2602681C true CA2602681C (en) | 2017-03-14 |
Family
ID=35998177
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2602681A Active CA2602681C (en) | 2006-01-17 | 2007-01-17 | Detecting and predicting pre-eclampsia |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7638287B2 (enExample) |
| EP (1) | EP1974220B1 (enExample) |
| JP (1) | JP2009524014A (enExample) |
| AT (1) | ATE504002T1 (enExample) |
| AU (1) | AU2007206756B2 (enExample) |
| CA (1) | CA2602681C (enExample) |
| DE (1) | DE602007013524D1 (enExample) |
| ES (1) | ES2364314T3 (enExample) |
| GB (1) | GB0600916D0 (enExample) |
| WO (1) | WO2007083099A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008098734A1 (en) | 2007-02-12 | 2008-08-21 | Stefan Hansson | Diagnosis and treatment of preeclampsia |
| GB0715030D0 (en) * | 2007-08-02 | 2007-09-12 | Wilson Carol J | Testing process |
| US8647832B2 (en) | 2008-01-25 | 2014-02-11 | Perkinelmer Health Sciences, Inc. | Methods for determining the risk of prenatal complications |
| CN102224422A (zh) * | 2008-11-20 | 2011-10-19 | 珀金埃尔默健康科学公司 | 使用pigf-2和pigf-3标志物确定先兆子痫风险的方法 |
| WO2010091253A1 (en) | 2009-02-06 | 2010-08-12 | Women & Infants' Hospital Of Rhode Island | Compositions, formulations and methods of treating preeclampsia-type disorders of pregnancy |
| AU2011231982B2 (en) * | 2010-03-24 | 2014-02-20 | Preelumina Diagnostics Ab | HbF and A1M as early stage markers for preeclampsia |
| WO2013087887A2 (en) * | 2011-12-15 | 2013-06-20 | Pronota N.V. | Biomarkers and parameters for hypertensive disorders of pregnancy |
| ES2718905T3 (es) * | 2012-04-24 | 2019-07-05 | Siemens Healthcare Diagnostics Inc | Métodos de examen de preeclampsia |
| WO2014124396A1 (en) * | 2013-02-08 | 2014-08-14 | University Of Iowa Research Foundation | Therapeutic strategies for the treatment of preeclampsia |
| US10119978B2 (en) * | 2013-03-15 | 2018-11-06 | Wallac Oy | System and method for determining risk of diabetes based on biochemical marker analysis |
| EP3189336B1 (en) | 2014-09-02 | 2018-11-07 | Wallac OY | Method for determining risk of pre-eclampsia |
| FR3037657B1 (fr) * | 2015-06-22 | 2017-06-23 | Univ Rouen Centre Hospitalier | Methode de diagnostic des troubles causes par l'alcoolisation foetale |
| US20200395127A1 (en) * | 2017-11-17 | 2020-12-17 | University Of Washington | Connected system for information-enhanced test results |
| EP4070113A4 (en) | 2019-12-04 | 2023-12-20 | Biora Therapeutics, Inc. | ASSESSMENT OF PREECAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR ASSAYS |
| GB2620035A (en) * | 2021-02-10 | 2023-12-27 | Mirvie Inc | Methods and systems for conducting pregnancy-related clinical trials |
| FR3157091A1 (fr) * | 2023-12-26 | 2025-06-27 | Universite De Montpellier | Prédiction du comportement biomécanique de la paroi artérielle à travers l’analyse temporelle du signal oscillométrique au cours de la mesure de pression |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5331298A (en) | 1996-12-23 | 1998-07-17 | Cambridge University Technical Services Limited | Diagnosis and treatment of pathological pregnancies |
| GB0026823D0 (en) | 2000-11-02 | 2000-12-20 | King S College London | Diagnosis of pre-eclampsia |
| US7435419B2 (en) * | 2002-07-19 | 2008-10-14 | Beth Israel Deaconess Medical Center | Methods of diagnosing and treating pre-eclampsia or eclampsia |
| GB0308967D0 (en) * | 2003-04-17 | 2003-05-28 | Univ London | Screen for pre-eclampsia |
| US7344892B2 (en) * | 2003-09-23 | 2008-03-18 | Beth Israel Deaconess Medical Center, Inc. | Screening for gestational disorders |
| CA2485722A1 (en) * | 2003-10-22 | 2005-04-22 | Paul Lehmann | Soluble transferrin receptor |
-
2006
- 2006-01-17 GB GBGB0600916.1A patent/GB0600916D0/en not_active Ceased
-
2007
- 2007-01-16 US US11/623,480 patent/US7638287B2/en not_active Expired - Fee Related
- 2007-01-17 WO PCT/GB2007/000123 patent/WO2007083099A1/en not_active Ceased
- 2007-01-17 AU AU2007206756A patent/AU2007206756B2/en active Active
- 2007-01-17 EP EP07700392A patent/EP1974220B1/en active Active
- 2007-01-17 CA CA2602681A patent/CA2602681C/en active Active
- 2007-01-17 DE DE602007013524T patent/DE602007013524D1/de active Active
- 2007-01-17 ES ES07700392T patent/ES2364314T3/es active Active
- 2007-01-17 AT AT07700392T patent/ATE504002T1/de not_active IP Right Cessation
- 2007-01-17 JP JP2008549934A patent/JP2009524014A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES2364314T8 (es) | 2011-09-22 |
| CA2602681A1 (en) | 2007-07-26 |
| AU2007206756A1 (en) | 2007-07-26 |
| US20070178530A1 (en) | 2007-08-02 |
| GB0600916D0 (en) | 2006-02-22 |
| AU2007206756B2 (en) | 2011-06-16 |
| EP1974220A1 (en) | 2008-10-01 |
| JP2009524014A (ja) | 2009-06-25 |
| EP1974220B1 (en) | 2011-03-30 |
| WO2007083099A1 (en) | 2007-07-26 |
| US7638287B2 (en) | 2009-12-29 |
| DE602007013524D1 (de) | 2011-05-12 |
| ATE504002T1 (de) | 2011-04-15 |
| HK1119244A1 (en) | 2009-02-27 |
| ES2364314T3 (es) | 2011-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2602681C (en) | Detecting and predicting pre-eclampsia | |
| CA2759534C (en) | Method for determining maternal health risks | |
| Albu et al. | Predictive factors for intrauterine growth restriction | |
| Khalil et al. | First trimester maternal serum placental protein 13 for the prediction of pre‐eclampsia in women with a priori high risk | |
| Odibo et al. | First-trimester placental protein 13, PAPP-A, uterine artery Doppler and maternal characteristics in the prediction of pre-eclampsia | |
| EP2368119B1 (en) | Method for determining the risk of preeclampsia using pigf-2 and pigf-3 markers | |
| Schneuer et al. | Angiopoietin 1 and 2 serum concentrations in first trimester of pregnancy as biomarkers of adverse pregnancy outcomes | |
| EP3189336B1 (en) | Method for determining risk of pre-eclampsia | |
| Yliniemi et al. | First trimester placental retinol-binding protein 4 (RBP4) and pregnancy-associated placental protein A (PAPP-A) in the prediction of early-onset severe pre-eclampsia | |
| Njoroge et al. | The interval between births and the risk of recurrent preeclampsia among predominantly high risk women in urban tertiary care center | |
| Kumar et al. | Role of sFLT-1/PlGF ratio in predicting severe adverse materno-fetal outcome in high risk women | |
| EP2550535B1 (en) | Hbf and a1m as early stage markers for preeclampsia | |
| Gharib et al. | Predictive value of maternal serum C-reactive protein levels with severity of preeclampsia | |
| Tussupkaliyev et al. | Urinary placental growth factor determined in the first trimester of pregnancy as a predictor of preeclampsia | |
| HK1119244B (en) | Detecting and predicting pre-eclampsia | |
| Kusuma | Current preeclampsia prediction model and biomarker | |
| JP2025500751A (ja) | 早発性子癇前症の予後についてのバイオマーカー | |
| MS | EARLY DETECTION OF HELLP SYNDROME USING BIOLOGICAL MARKERS AND DOPPLER ULTRASONOGRAPHY |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |